AU2002952492A0 - Chaperonin 10 immunosuppression - Google Patents

Chaperonin 10 immunosuppression

Info

Publication number
AU2002952492A0
AU2002952492A0 AU2002952492A AU2002952492A AU2002952492A0 AU 2002952492 A0 AU2002952492 A0 AU 2002952492A0 AU 2002952492 A AU2002952492 A AU 2002952492A AU 2002952492 A AU2002952492 A AU 2002952492A AU 2002952492 A0 AU2002952492 A0 AU 2002952492A0
Authority
AU
Australia
Prior art keywords
donor
recipient animal
cpn10
administration
host disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002952492A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CBio Ltd
Original Assignee
CBio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CBio Ltd filed Critical CBio Ltd
Priority to AU2002952492A priority Critical patent/AU2002952492A0/en
Publication of AU2002952492A0 publication Critical patent/AU2002952492A0/en
Priority to PT03769073T priority patent/PT1569679E/pt
Priority to KR1020057008096A priority patent/KR101088740B1/ko
Priority to US10/534,193 priority patent/US7618935B2/en
Priority to AT03769073T priority patent/ATE489963T1/de
Priority to PCT/AU2003/001467 priority patent/WO2004041300A1/en
Priority to AU2003277992A priority patent/AU2003277992B2/en
Priority to EP14177983.5A priority patent/EP2818179A1/en
Priority to DE60335202T priority patent/DE60335202D1/de
Priority to NZ540433A priority patent/NZ540433A/en
Priority to CNB2003801082969A priority patent/CN100525832C/zh
Priority to EP10174226.0A priority patent/EP2255824B1/en
Priority to ES03769073T priority patent/ES2351993T3/es
Priority to DK03769073.2T priority patent/DK1569679T3/da
Priority to EP03769073A priority patent/EP1569679B1/en
Priority to JP2004548934A priority patent/JP4716731B2/ja
Priority to CA2505141A priority patent/CA2505141C/en
Priority to SI200331912T priority patent/SI1569679T1/sl
Priority to US12/572,195 priority patent/US8067361B2/en
Priority to CY20101101115T priority patent/CY1110972T1/el
Priority to JP2010286005A priority patent/JP2011088920A/ja
Priority to US13/290,996 priority patent/US20120082690A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Glass Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2002952492A 2002-11-06 2002-11-06 Chaperonin 10 immunosuppression Abandoned AU2002952492A0 (en)

Priority Applications (22)

Application Number Priority Date Filing Date Title
AU2002952492A AU2002952492A0 (en) 2002-11-06 2002-11-06 Chaperonin 10 immunosuppression
SI200331912T SI1569679T1 (sl) 2002-11-06 2003-11-06 Imunosupresija s šaperoninom 10
CNB2003801082969A CN100525832C (zh) 2002-11-06 2003-11-06 伴侣蛋白10的免疫抑制作用
ES03769073T ES2351993T3 (es) 2002-11-06 2003-11-06 Inmunosupresión mediante chaperonina 10.
US10/534,193 US7618935B2 (en) 2002-11-06 2003-11-06 Chaperonin 10 immunosuppression
AT03769073T ATE489963T1 (de) 2002-11-06 2003-11-06 Chaperonin-10-immunosuppression
PCT/AU2003/001467 WO2004041300A1 (en) 2002-11-06 2003-11-06 Chaperonin 10 immunosuppression
AU2003277992A AU2003277992B2 (en) 2002-11-06 2003-11-06 Chaperonin 10 immunosuppression
EP14177983.5A EP2818179A1 (en) 2002-11-06 2003-11-06 Chaperonin 10 immunosuppression
DE60335202T DE60335202D1 (en) 2002-11-06 2003-11-06 Chaperonin-10-immunosuppression
NZ540433A NZ540433A (en) 2002-11-06 2003-11-06 Treatment and management graft versus host disease (GVHD) by administering chaperonin 10 (cpn10) to a recipient animal
PT03769073T PT1569679E (pt) 2002-11-06 2003-11-06 Imunossupressão com chaperonina 10
EP10174226.0A EP2255824B1 (en) 2002-11-06 2003-11-06 Chaperonin 10 for use in treatment of graft versus host disease (GVHD) alone or in combination with another immunosuppressive agent or a steroid
KR1020057008096A KR101088740B1 (ko) 2002-11-06 2003-11-06 샤페로닌 10을 이용한 면역억제 방법
DK03769073.2T DK1569679T3 (da) 2002-11-06 2003-11-06 Chaperonin-10-immunosuppression
EP03769073A EP1569679B1 (en) 2002-11-06 2003-11-06 Chaperonin 10 immunosuppression
JP2004548934A JP4716731B2 (ja) 2002-11-06 2003-11-06 シャペロニン１０免疫抑制
CA2505141A CA2505141C (en) 2002-11-06 2003-11-06 Chaperonin 10 immunosuppression
US12/572,195 US8067361B2 (en) 2002-11-06 2009-10-01 Chaperonin 10 immunosuppression
CY20101101115T CY1110972T1 (el) 2002-11-06 2010-12-03 Ανοσοκαταστολη με σαπερονινη 10
JP2010286005A JP2011088920A (ja) 2002-11-06 2010-12-22 シャペロニン１０免疫抑制
US13/290,996 US20120082690A1 (en) 2002-11-06 2011-11-07 Chaperonin 10 immunosuppression

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU2002952492A AU2002952492A0 (en) 2002-11-06 2002-11-06 Chaperonin 10 immunosuppression

Publications (1)

Publication Number Publication Date
AU2002952492A0 true AU2002952492A0 (en) 2002-11-21

Family

ID=28795882

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002952492A Abandoned AU2002952492A0 (en) 2002-11-06 2002-11-06 Chaperonin 10 immunosuppression

Country Status (16)

Country Link
US (3) US7618935B2 (cg-RX-API-DMAC7.html)
EP (3) EP1569679B1 (cg-RX-API-DMAC7.html)
JP (2) JP4716731B2 (cg-RX-API-DMAC7.html)
KR (1) KR101088740B1 (cg-RX-API-DMAC7.html)
CN (1) CN100525832C (cg-RX-API-DMAC7.html)
AT (1) ATE489963T1 (cg-RX-API-DMAC7.html)
AU (1) AU2002952492A0 (cg-RX-API-DMAC7.html)
CA (1) CA2505141C (cg-RX-API-DMAC7.html)
CY (1) CY1110972T1 (cg-RX-API-DMAC7.html)
DE (1) DE60335202D1 (cg-RX-API-DMAC7.html)
DK (1) DK1569679T3 (cg-RX-API-DMAC7.html)
ES (1) ES2351993T3 (cg-RX-API-DMAC7.html)
NZ (1) NZ540433A (cg-RX-API-DMAC7.html)
PT (1) PT1569679E (cg-RX-API-DMAC7.html)
SI (1) SI1569679T1 (cg-RX-API-DMAC7.html)
WO (1) WO2004041300A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ548985A (en) * 2004-01-16 2010-02-26 Cbio Ltd Chaperonin 10 modulation of toll-like receptor-inducible cytokine and chemokine secretion
AU2005204979B2 (en) * 2004-01-16 2010-10-21 Cbio Limited Chaperonin 10 modulation of toll-like receptor-inducible cytokine and chemokine secretion
US8036710B2 (en) * 2004-05-07 2011-10-11 Qualcomm, Incorporated Power-efficient multi-antenna wireless device
CA2614480A1 (en) * 2005-07-11 2007-01-18 Cbio Limited Chaperonin 10-induced immunomodulation
AU2006269824B2 (en) * 2005-07-11 2012-04-19 Cbio Limited Chaperonin 10-induced immunomodulation
WO2007025343A1 (en) 2005-08-31 2007-03-08 Cbio Limited Modified chaperonin 10
AU2006303826B2 (en) * 2005-10-20 2012-07-19 Cbio Limited Treatment of hypersensitivity
CN101330922A (zh) * 2005-10-20 2008-12-24 悉生物有限公司 超敏的治疗
KR20090003310A (ko) 2006-03-02 2009-01-09 씨바이오 리미티드 항원 제시 세포의 기능 조절에 의한 면역 반응의 조절
RU2010145972A (ru) * 2008-04-11 2012-05-20 СиБАЙО ЛИМИТЕД (AU) МОДИФИЦИРОВАННЫЙ Cpn10 И ПЕРЕДАЧА СИГНАЛА PRR
US20110243921A1 (en) * 2010-03-30 2011-10-06 Cbio Limited Prevention and treatment of cutaneous lupus erythematosus
WO2013158959A1 (en) * 2012-04-19 2013-10-24 Tarix Pharmaceuticals Ltd. Compositions and methods for treatment of graft-versus-host disease
US9688741B2 (en) 2012-10-23 2017-06-27 Elastagen Pty Ltd Elastic hydrogel
KR102239867B1 (ko) 2012-12-10 2021-04-13 앨러간 파마슈티컬스 인터내셔널 리미티드 확장 가능한 3-차원 탄성 구조물 제조
CA2920312C (en) 2013-08-13 2022-07-19 Elastagen Pty Ltd Regeneration of damaged tissue

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2176948C (en) * 1993-11-30 2007-05-15 Halle Morton Chaperonin 10
EP0733071A4 (en) * 1993-11-30 1997-02-26 Univ Queensland ANTAGONISTS OF CHAPERONINE 10
US5989804A (en) * 1994-07-08 1999-11-23 New England Medical Center Hospitals, Inc. E6 binding proteins
WO1997005896A1 (en) * 1995-08-09 1997-02-20 Schering Corporation Combined use of interleukin-10 and cyclosporin for immunosuppression therapy
US20020142000A1 (en) * 1999-01-15 2002-10-03 Digan Mary Ellen Anti-CD3 immunotoxins and therapeutic uses therefor
CA2383213A1 (en) * 1999-09-10 2001-03-15 Fordham University Methods and compositions for the treatment and prevention of graft rejection using heat shock proteins
GB0028122D0 (en) * 2000-11-17 2001-01-03 St Georges Entpr Ltd Method

Also Published As

Publication number Publication date
EP1569679A1 (en) 2005-09-07
US20100099605A1 (en) 2010-04-22
NZ540433A (en) 2008-03-28
US20120082690A1 (en) 2012-04-05
CA2505141A1 (en) 2004-05-21
EP1569679B1 (en) 2010-12-01
CY1110972T1 (el) 2015-06-11
DE60335202D1 (en) 2011-01-13
KR101088740B1 (ko) 2011-12-01
WO2004041300A1 (en) 2004-05-21
ES2351993T3 (es) 2011-02-14
JP2011088920A (ja) 2011-05-06
EP2255824B1 (en) 2014-07-23
CA2505141C (en) 2012-07-17
US8067361B2 (en) 2011-11-29
DK1569679T3 (da) 2011-01-10
SI1569679T1 (sl) 2011-01-31
CN1735428A (zh) 2006-02-15
EP2255824A1 (en) 2010-12-01
JP2006508099A (ja) 2006-03-09
ATE489963T1 (de) 2010-12-15
EP2818179A1 (en) 2014-12-31
JP4716731B2 (ja) 2011-07-06
US7618935B2 (en) 2009-11-17
US20060198834A1 (en) 2006-09-07
PT1569679E (pt) 2010-12-14
CN100525832C (zh) 2009-08-12
KR20050086428A (ko) 2005-08-30
EP1569679A4 (en) 2008-02-27

Similar Documents

Publication Publication Date Title
CY1110972T1 (el) Ανοσοκαταστολη με σαπερονινη 10
WO2004028243A3 (en) Porcine animals lacking any expression of functional alpha 1,3 galactosyltransferase
WO1999062425A3 (en) Bioengineered vascular graft prostheses
BR0203650A (pt) Estentor de auto-articulação
EP1487431A4 (en) PREVENTING AND / OR TREATING CARDIOVASCULAR DISEASE AND / OR RELATED CARDIAC INSUFFICIENCY
EP1688425A3 (en) Cyclic salen-metal compounds as scavengers for oxygen radicals and useful as antioxidants in the treatment and prevention of diseases
WO2000012112A3 (en) Treatment of lesions with xanthine oxidoreductase
CA2158638A1 (en) A Composition and a Method for Tissue Augmentation
WO1999062424A3 (en) Bioengineered tubular graft prostheses
WO2004039248A3 (en) Repairing or replacing tissues or organs
SI1546088T1 (sl) Spojine za uporabo v zdravljenju avtoimunskih bolezni, imunoalergijskih bolezni in zavrnitve transpalantata organa ali tkiva
AU2003222513A1 (en) Preventing and/or treating vascular disease, cardiomyopathy and/or associated heart failure
EP2364708A3 (en) Pharmaceutical composition comprising a ClC-2 channel opener
SI1567171T1 (sl) Uporaba dekstran sulfata za zdravljenje IBMIR
BR9612821A (pt) Métodos para a prevenção de rejeição de enxerto em transplante e para a produção de uma célula de hospedeiro para terapia genética universal
WO2001068828A3 (en) Compositions and methods for regulated protein expression in gut
HU901516D0 (en) The use of s-adenosile-methionine in the treatment of pancreatitis, and in preventing the natural rejection of transplanted pancreas
WO2003102162A3 (en) Novel tolerogenic dendritic cells and therapeutic uses therefor
DE3875306D1 (de) Immunosuppression bei der auf immunotoxin basierten behandlung von menschen.
EP1964572A3 (en) Compositions and methods for protecting organs, tissue and cells from immune system-mediated damage
CA2283450A1 (en) Methods for treatment of scar tissue
CA2267059A1 (en) Sordarin derivatives
MXPA05004121A (es) Metodos para tratar la enfermedad de ojo reseco con lantibioticos.
Godwin et al. Reconstruction of a large defect of the ear using a composite graft following a human bite injury
PL338678A1 (en) Derivatives of 4-cyano-4-deformylsordacin